Phenotypic cross-resistance to nelfinavir: The role of prior antiretroviral therapy and the number of mutations in the protease gene

AIDS Research and Human Retroviruses

Volumn 17, Issue 3, 2001, Pages 211-215

  Dronda, F ^a   Casado, J L ^a   Moreno, S ^a   Hertogs, K ^b   Garcia Arata I ^a   Antela, A ^a   Perez Elias M J ^a   Ruiz, L ^c   Larder, B ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Virco BVBA   (Belgium)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Virco UK Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CROSS RESISTANCE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; STRAIN DIFFERENCE; VIRUS MORPHOLOGY; VIRUS MUTATION;

ADULT; AGED; ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; NELFINAVIR; PHENOTYPE;

EID: 0035835499     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201750063124     Document Type: Article

References (17)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. BHIVA guidelines writing committee 1998 revision to the British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals
3. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
4. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society-USA panel
5. Resistance to human immunodeficiency virus type I protease inhibitors
6. Nelfinavir: A review of its therapeutic efficacy in HIV infection
7. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
8. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
9. Genotypic and phenotypic characterization of human immunodeficiency virus type I variants isolated from patients treated with the protease inhibitor nelfinavir
10. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
11. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virological outcome
12. Impact of drug resistance mutations on virologic response to salvage therapies
13. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
14. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis
15. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
16. Virologic responses to ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
17. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors